Predictors of placebo response in restless legs syndrome studies
Restless legs syndrome (RLS) is a highly prevalent sensorimotor disorder. Effective treatments for RLS have been established in large placebo-controlled trials. These trials have generally employed the International RLS Rating Scale (IRLS) (range 0-40)[1] and Clinical Global Impression of Change (CG...
Gespeichert in:
| Veröffentlicht in: | Neurology 2013-07, Vol.81 (2), p.193-194 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 2 |
| container_start_page | 193 |
| container_title | Neurology |
| container_volume | 81 |
| creator | Ondo, William G Hossain, Md Monir Gordon, Mark Forrest Reess, Juergen |
| description | Restless legs syndrome (RLS) is a highly prevalent sensorimotor disorder. Effective treatments for RLS have been established in large placebo-controlled trials. These trials have generally employed the International RLS Rating Scale (IRLS) (range 0-40)[1] and Clinical Global Impression of Change (CGI). The interpretation of clinical trials has been mitigated by a large placebo response for both the IRLS and CGI.[2] We wished to evaluate specific patient, scale, and trial design predictors of placebo response. |
| doi_str_mv | 10.1212/WNL.0b013e31829a33bd |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1547863414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1547863414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3456-b8b4536db2c7cc0c5ff8dfe9f8b4f56ffb93e6005e7ed7e86b32884d7b3254433</originalsourceid><addsrcrecordid>eNqFkElvFDEQhS0EIkPgHyDUFyQuHbwvN1AUFmmU5ACCW8tLmTR4ugdXt6L8exwygJQLvpT1_FW98iPkOaMnjDP--sv59oQGygQIZrnzQoT0gGyY4rrXgn99SDaUctsLa-wReYL4ndL2aNxjcsSFkc44tyFvLiukMS5zxW7O3b74CGHuKuB-nhC6cbq9LwUQuwLfsMObKdV5Bx0uaxoBn5JH2ReEZ4d6TD6_O_t0-qHfXrz_ePp220chle6DDVIJnQKPJkYaVc42ZXC56VnpnIMToClVYCAZsDoIbq1MplUlpRDH5NXd3H2df65tpWE3YoRS_ATzigNT0lgtJJP_R4VzXCvHaEPlHRrrjFghD_s67ny9GRgdbmMeWszD_Zhb24uDwxp2kP42_cm1AS8PgMfoS65-iiP-44xixvz-1cH_ei4LVPxR1muowxX4slwNtB3NmOx586eGOto3hWnxC8bqlng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399265910</pqid></control><display><type>article</type><title>Predictors of placebo response in restless legs syndrome studies</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ondo, William G ; Hossain, Md Monir ; Gordon, Mark Forrest ; Reess, Juergen</creator><creatorcontrib>Ondo, William G ; Hossain, Md Monir ; Gordon, Mark Forrest ; Reess, Juergen</creatorcontrib><description>Restless legs syndrome (RLS) is a highly prevalent sensorimotor disorder. Effective treatments for RLS have been established in large placebo-controlled trials. These trials have generally employed the International RLS Rating Scale (IRLS) (range 0-40)[1] and Clinical Global Impression of Change (CGI). The interpretation of clinical trials has been mitigated by a large placebo response for both the IRLS and CGI.[2] We wished to evaluate specific patient, scale, and trial design predictors of placebo response.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0b013e31829a33bd</identifier><identifier>PMID: 23749799</identifier><identifier>CODEN: NEURAI</identifier><language>eng</language><publisher>Hagerstown, MD: American Academy of Neurology</publisher><subject>Adult ; Benzothiazoles - therapeutic use ; Biological and medical sciences ; Dopamine Agonists - therapeutic use ; Female ; Humans ; Male ; Malformations of the nervous system ; Medical sciences ; Neurology ; Placebo Effect ; Placebos - therapeutic use ; Predictive Value of Tests ; Randomized Controlled Trials as Topic - standards ; Research Design - standards ; Restless Legs Syndrome - drug therapy ; Treatment Outcome</subject><ispartof>Neurology, 2013-07, Vol.81 (2), p.193-194</ispartof><rights>2013 American Academy of Neurology</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3456-b8b4536db2c7cc0c5ff8dfe9f8b4f56ffb93e6005e7ed7e86b32884d7b3254433</citedby><cites>FETCH-LOGICAL-c3456-b8b4536db2c7cc0c5ff8dfe9f8b4f56ffb93e6005e7ed7e86b32884d7b3254433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27517743$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23749799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ondo, William G</creatorcontrib><creatorcontrib>Hossain, Md Monir</creatorcontrib><creatorcontrib>Gordon, Mark Forrest</creatorcontrib><creatorcontrib>Reess, Juergen</creatorcontrib><title>Predictors of placebo response in restless legs syndrome studies</title><title>Neurology</title><addtitle>Neurology</addtitle><description>Restless legs syndrome (RLS) is a highly prevalent sensorimotor disorder. Effective treatments for RLS have been established in large placebo-controlled trials. These trials have generally employed the International RLS Rating Scale (IRLS) (range 0-40)[1] and Clinical Global Impression of Change (CGI). The interpretation of clinical trials has been mitigated by a large placebo response for both the IRLS and CGI.[2] We wished to evaluate specific patient, scale, and trial design predictors of placebo response.</description><subject>Adult</subject><subject>Benzothiazoles - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Malformations of the nervous system</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Placebo Effect</subject><subject>Placebos - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Randomized Controlled Trials as Topic - standards</subject><subject>Research Design - standards</subject><subject>Restless Legs Syndrome - drug therapy</subject><subject>Treatment Outcome</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElvFDEQhS0EIkPgHyDUFyQuHbwvN1AUFmmU5ACCW8tLmTR4ugdXt6L8exwygJQLvpT1_FW98iPkOaMnjDP--sv59oQGygQIZrnzQoT0gGyY4rrXgn99SDaUctsLa-wReYL4ndL2aNxjcsSFkc44tyFvLiukMS5zxW7O3b74CGHuKuB-nhC6cbq9LwUQuwLfsMObKdV5Bx0uaxoBn5JH2ReEZ4d6TD6_O_t0-qHfXrz_ePp220chle6DDVIJnQKPJkYaVc42ZXC56VnpnIMToClVYCAZsDoIbq1MplUlpRDH5NXd3H2df65tpWE3YoRS_ATzigNT0lgtJJP_R4VzXCvHaEPlHRrrjFghD_s67ny9GRgdbmMeWszD_Zhb24uDwxp2kP42_cm1AS8PgMfoS65-iiP-44xixvz-1cH_ei4LVPxR1muowxX4slwNtB3NmOx586eGOto3hWnxC8bqlng</recordid><startdate>20130709</startdate><enddate>20130709</enddate><creator>Ondo, William G</creator><creator>Hossain, Md Monir</creator><creator>Gordon, Mark Forrest</creator><creator>Reess, Juergen</creator><general>American Academy of Neurology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130709</creationdate><title>Predictors of placebo response in restless legs syndrome studies</title><author>Ondo, William G ; Hossain, Md Monir ; Gordon, Mark Forrest ; Reess, Juergen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3456-b8b4536db2c7cc0c5ff8dfe9f8b4f56ffb93e6005e7ed7e86b32884d7b3254433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Benzothiazoles - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Malformations of the nervous system</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Placebo Effect</topic><topic>Placebos - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Randomized Controlled Trials as Topic - standards</topic><topic>Research Design - standards</topic><topic>Restless Legs Syndrome - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ondo, William G</creatorcontrib><creatorcontrib>Hossain, Md Monir</creatorcontrib><creatorcontrib>Gordon, Mark Forrest</creatorcontrib><creatorcontrib>Reess, Juergen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ondo, William G</au><au>Hossain, Md Monir</au><au>Gordon, Mark Forrest</au><au>Reess, Juergen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of placebo response in restless legs syndrome studies</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2013-07-09</date><risdate>2013</risdate><volume>81</volume><issue>2</issue><spage>193</spage><epage>194</epage><pages>193-194</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><coden>NEURAI</coden><abstract>Restless legs syndrome (RLS) is a highly prevalent sensorimotor disorder. Effective treatments for RLS have been established in large placebo-controlled trials. These trials have generally employed the International RLS Rating Scale (IRLS) (range 0-40)[1] and Clinical Global Impression of Change (CGI). The interpretation of clinical trials has been mitigated by a large placebo response for both the IRLS and CGI.[2] We wished to evaluate specific patient, scale, and trial design predictors of placebo response.</abstract><cop>Hagerstown, MD</cop><pub>American Academy of Neurology</pub><pmid>23749799</pmid><doi>10.1212/WNL.0b013e31829a33bd</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2013-07, Vol.81 (2), p.193-194 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1547863414 |
| source | Journals@Ovid Ovid Autoload; MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Benzothiazoles - therapeutic use Biological and medical sciences Dopamine Agonists - therapeutic use Female Humans Male Malformations of the nervous system Medical sciences Neurology Placebo Effect Placebos - therapeutic use Predictive Value of Tests Randomized Controlled Trials as Topic - standards Research Design - standards Restless Legs Syndrome - drug therapy Treatment Outcome |
| title | Predictors of placebo response in restless legs syndrome studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T15%3A30%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20placebo%20response%20in%20restless%20legs%20syndrome%20studies&rft.jtitle=Neurology&rft.au=Ondo,%20William%20G&rft.date=2013-07-09&rft.volume=81&rft.issue=2&rft.spage=193&rft.epage=194&rft.pages=193-194&rft.issn=0028-3878&rft.eissn=1526-632X&rft.coden=NEURAI&rft_id=info:doi/10.1212/WNL.0b013e31829a33bd&rft_dat=%3Cproquest_cross%3E1547863414%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1399265910&rft_id=info:pmid/23749799&rfr_iscdi=true |